Crowdonomics
WatchlistPortfolio
All companies

SpotitEarly, Inc.

Raising nowOperating

Healthcare · Englewood, NJ

SpotitEarly is developing a non-invasive cancer pre-screening test that combines trained dogs' sense of smell with AI analysis of breath samples. The test is meant to detect several cancers from one sample, starting with lung, breast, prostate and colorectal, and to be done at home or in a clinic.

Raising nowRaising now

This company has an open fundraising round.

$0 raised
View the live round
Estimated pre-money ⓘ
$143.7M
As of Jan 2026 · from Reg A Offering (2025) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$10,000
Crowd $0 · Private $10K · 2 rounds since 2025
Latest share price
$7.15
Reg A+ · Equity · Jan 2026 offering price

Financials

FY2024–FY2025 · from SEC filings · hover any figure for its source
$0
−$6.1M
2024
−$6.0M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2024 audited
FY2025 audited
Income statement
Revenue
$0
—
Cost of goods sold
$0
—
Net income
-$6,120,000
-$5,953,000
Balance sheet
Cash
$5,240,000
$1,836,000
Accounts receivable
$0
—
Total assets
$7,262,000
$5,038,000
Long-term debt
$0
—
Total liabilities
$12,829,000
$959,000
Other
Headcount
23
—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$143.7M
est. pre-money
Reg A+ · Equity · Jan 2026

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Jan 16, 2026
Preferred Equity · 57.2%Common Stock · 42.8%
ClassOutstandingVotes / shareShare of totalLast price
Preferred Equitypreferred11,627,834—57.2%—
Common Stock8,684,618142.8%$7.15Jan 2026
Total20,312,452100%

Shares outstanding over timein today's share terms

20M10M0
Jul 2025Dec 2025
Common StockPreferred Equity

Changes in named holdersshares in today's terms · % of all shares at the time

Principal holders% as the filing states it, Jan 16, 2026

  • Two International Place Boston5,956,067 shares51.1%of company
  • Igal Alon9 shares20.0%of company
  • Alon Lifschitz4,059,084 shares20.0%of company
  • Roi Ophir3,044,897 shares14.9%of company
  • Sunnyvale2,787,775 shares14.9%of company
  • Ariel Ben Dayan2,923,102 shares14.4%of company
  • Veidat Katowitz31 shares14.4%of company
  • Ohad Sharon2,574,241 shares12.6%of company
  • Sidney W. Swartz1,182,790 shares5.9%of company
  • Hamaapil Israel3,885,700 shares5.9%of company
  • Shlomi Madar198,615 Common1%of company
  • J. Leonard Lichtenfeld99,219 Common0.5%of company
  • Shai Lankry49,610 Common0.2%of company
  • Asaf Ruf33,073 Common0.2%of company

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Reg A+ · Equity · Jan 2026Open
Raised $0 / $69.4MEst. pre-money $143.7M
Rule 506(c) · Equity · Jul 2025Closed
Raised $10KInvestors 1

Team

7 people
Shlomi Madar
Chief Executive Officer and a Director
Assaf Ruf
Vice President of Research and Development
J. Leonard Lichtenfeld
Chief Medical Officer
Shai Lankry
Chief Financial Officer and a Director
Alon Lifschitz
Director
Ariel Ben Dayan
Director
Roi Ophir
Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

SEC filings

View all 11 filings on EDGAR
  • Form 1-SASep 30, 20260001096906-26-001483
    EDGAR
  • Form 1-KMay 8, 20260001096906-26-000746
    EDGAR
  • Form 253G2Mar 27, 20260001096906-26-000393
    EDGAR
  • Form 253G2Feb 12, 20260001096906-26-000235
    EDGAR
  • Form QUALIFJan 28, 20269999999994-26-000024
    EDGAR
  • Form 1-A/AJan 16, 20260001096906-26-000101
    EDGAR
  • Form 1-A/ADec 31, 20250001096906-25-002188
    EDGAR
  • Form 1-A/ANov 26, 20250001096906-25-001941
    EDGAR
Source: SEC EDGARCIK 0002077992DEShare price $7.15Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.